The efficacy and safety of JAK inhibitor in inflammatory osteoarthritis

The efficacy and safety of JAK inhibitor in inflammatory knee osteoarthritis

Status

Recruiting

Phases

Phase 4

Study type

Observational

Source

ChiCTR

Registry ID

ChiCTR2100050394

Enrollment

Unknown

Registered

2021-08-27

Start date

2021-09-01

Completion date

Unknown

Last updated

2022-04-25

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Osteoarthritis

Interventions

Janus kinase(JAK) inhibitor:Nil

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Inclusion criteria

Inclusion criteria: 1. Aged >= 18 years; 2. Non-respond to NSAIDs for 4 weeks; 3. Swelling and tenderness of knees confirmed by physician; 4. A high erythrocyte sedimentation rate.

Exclusion criteria

Exclusion criteria: 1. Other inflammatory arthritis,such as rheumatoid arthritis and peripheral spondyloarthritis; 2. History of tuberculosis; 3. History of tumor; 4. Female in pregnancy or lactation; 5. Allergy to JAK inhibitor; 6. Severe disfunction of liver or kidney.

Design outcomes

Primary

Measure	Time frame
Visual analogue scale (VAS);	—

Countries

China

Contacts

Public ContactWang Qian

Shanghai Sixth People's Hospital

wangqian198886@163.com+86 15601918612

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026